Nonteratogenicity of a structural analog of thalidomide in pregnant baboons (Papio cynocephalus)

Andrew G Hendrickx, F. ‐Ch Helm

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Teratologic evaluation of a mild tranquilizer being developed for human therapeutic use involved daily oral administration to 29 baboons P. cynocephalus during organogenesis according to three treatment regimens. In Phase I, 9 animals (3 groups of 3) received 2, 6, or 20 mg/kg CG 3033 per day for 28 consecutive days between 18 and 45 days gestation; in Phase II, 14 animals (7 groups of 2) were given 20 mg/kg CG 3033 for four consecutive days: 18–21, 22–25, 26–29, 30–33, 34–37, 38–41, or 42–45; and in Phase III, 6 animals (2 groups of 3) were administered 40 mg/kg daily between days 18–21 or 22–25 of gestation. No teratologic changes attributable to drug treatment were observed, and the abortion rate was within the range for controls.

Original languageEnglish (US)
Pages (from-to)179-182
Number of pages4
JournalTeratology
Volume22
Issue number2
DOIs
StatePublished - 1980

ASJC Scopus subject areas

  • Embryology
  • Toxicology
  • Developmental Biology
  • Health, Toxicology and Mutagenesis

Fingerprint Dive into the research topics of 'Nonteratogenicity of a structural analog of thalidomide in pregnant baboons (Papio cynocephalus)'. Together they form a unique fingerprint.

Cite this